Successful Sirolimus Treatment for Korean Patients with Activated Phosphoinositide 3-kinase δ Syndrome 1: the First Case Series in Korea
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Activated phosphoinositide 3-kinase δ syndrome (APDS)1 is caused by gain-of-function mutations in PIK3CD, which encodes the catalytic p110δ subunit of phosphoinositide 3 kinase. We describe three patients with APDS1, the first thereof in Korea. Therein, we investigated clinical manifestations of APDS1 and collected data on the efficacy and safety profile of sirolimus, a mammalian target of rapamycin inhibitor and pathway-specific targeted medicine. The same heterozygous PIK3CD mutation was detected in all three patients (E1021K). After genetic diagnosis, all patients received sirolimus and experienced an excellent response, including amelioration of lymphoproliferation and improvement of nodular mucosal lymphoid hyperplasia in the gastrointestinal tract. The median trough level of sirolimus was 5.5 ng/mL (range, 2.8–7.5) at a dose of 2.6–3.6 mg/m2. Two patients who needed highdose, short-interval, immunoglobulin-replacement treatment (IGRT) had a reduced requirement for IGRT after initiating sirolimus, and the dosing interval was extended from 2 and 3 weeks to 4 weeks. The IgG trough level after sirolimus treatment (median, 594 mg/dL; range, 332–799 mg/dL) was significantly higher than that before sirolimus treatment (median, 290 mg/dL; range, 163–346 mg/dL) (p<0.001). One episode of elevated serum creatinine with a surge of sirolimus (Patient 2) and episodes of neutropenia and oral stomatitis (Patient 1) were observed. We diagnosed the first three patients with APDS1 in Korea. Low-dose sirolimus may alleviate clinical manifestations thereof, including hypogammaglobulinemia.
Abstract
Activated phosphoinositide 3-kinase δ syndrome (APDS)1 is caused by gain-of-function mutations in PIK3CD, which encodes the catalytic p110δ subunit of phosphoinositide 3 kinase. We describe three patients with APDS1, the first thereof in Korea. Therein, we investigated clinical manifestations of APDS1 and collected data on the efficacy and safety profile of sirolimus, a mammalian target of rapamycin inhibitor and pathway-specific targeted medicine. The same heterozygous PIK3CD mutation was detected in all three patients (E1021K). After genetic diagnosis, all patients received sirolimus and experienced an excellent response, including amelioration of lymphoproliferation and improvement of nodular mucosal lymphoid hyperplasia in the gastrointestinal tract. The median trough level of sirolimus was 5.5 ng/mL (range, 2.8–7.5) at a dose of 2.6–3.6 mg/m2. Two patients who needed highdose, short-interval, immunoglobulin-replacement treatment (IGRT) had a reduced requirement for IGRT after initiating sirolimus, and the dosing interval was extended from 2 and 3 weeks to 4 weeks. The IgG trough level after sirolimus treatment (median, 594 mg/dL; range, 332–799 mg/dL) was significantly higher than that before sirolimus treatment (median, 290 mg/dL; range, 163–346 mg/dL) (p<0.001). One episode of elevated serum creatinine with a surge of sirolimus (Patient 2) and episodes of neutropenia and oral stomatitis (Patient 1) were observed. We diagnosed the first three patients with APDS1 in Korea. Low-dose sirolimus may alleviate clinical manifestations thereof, including hypogammaglobulinemia.
참고문헌 (11)
- Lucas CL, "Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency", Nat Immunol, 15, pp.88~97 (2014)
- Coulter TI, "Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome : a large patient cohort study", J Allergy Clin Immunol, 139, pp.597~606 (2017)
- Bravo García-Morato M, "Mutations in PIK3R1 can lead to APDS2, SHORT syndrome or a combination of the two", Clin Immunol, 179, pp.77~80 (2017)
- Deau MC, "A human immunodeficiency caused by mutations in the PIK3R1 gene", J Clin Invest, 124, pp.3923~3928 (2014)
- Pongas G, "PI3K signaling pathway in normal B cells and indolent B-cell malignancies", Semin Oncol, 43, pp.647~654 (2016)
- Vivanco I, "The phosphatidylinositol 3-Kinase AKT pathway in human cancer", Nat Rev Cancer, 2, pp.489~501 (2002)
- Pauls SD, "The phosphoinositide 3-kinase signaling pathway in normal and malignant B cells : activation mechanisms, regulation and impact on cellular functions", Front Immunol, 3, pp.224~ (2012)
- Rae W, "Precision treatment with sirolimus in a case of activated phosphoinositide 3-kinase δ syndrome", Clin Immunol, 171, pp.38~40 (2016)
- Rao VK, "Effective"activated PI3Kδ syndrome"-targeted therapy with the PI3Kδ inhibitor leniolisib", Blood, 130, pp.2307~2316 (2017)
- Maccari ME, "Disease evolution and response to rapamycin in activated phosphoinositide 3-kinase δ syndrome : The European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase δ Syndrome Registry", Front Immunol, 9, pp.543~ (2018)
- De Simone P, "Use of everolimus in liver transplantation : recommendations from a working group", Transplantation, 101, pp.239~251 (2017)